Friday, June 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Science Moving towArds Research Translation and Therapy (SMARTT)

by Global Biodefense Staff
March 13, 2016
Ebola Research Targets

To bridge the gap that exists in moving scientific discoveries to clinical application, the National Heart, Lung, and Blood Institutes (NHLBI) established and supports a Science Moving towArds Research Translation and Therapy (SMARTT) program for the production and testing of novel therapeutics to treat heart, lung, and blood diseases.

The program serves NHLBI investigators, provides consulting, manufacturing, pharmacology and toxicology testing; preclinical and early phase clinical study design support; and administrative and regulatory expertise.

In November of 2010, the NHLBI awarded four contracts to establish the SMARTT Program infrastructure to provide tailored pharmacology and toxicology testing, manufacturing services, and regulatory support to investigators to expedite the transition of their discoveries to the clinic.

Last week, each of these original contractors were awarded 36-month follow-on SMARTT Program contracts in the following amounts:

  • SMARTT Coordinating Center: RTI International $2,996,149
  • SMARTT Biologics Production Facility: Advanced Bioscience Laboratories $5,765,185
  • SMARTT Non-Biologics & Small Molecules Production Facility: SRI International $3,250,682
  • SMARTT Pharmacology & Toxicology Center: SRI International $4,365,236

The investment into this program by NHLBI is yielding more output in terms of numbers of Investigational New Drugs (INDs) than would occur if investigators had to seek out the necessary IND-enabling services on their own.

Tags: Awards

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy